SAN FRANCISCO —Medical treatments for addressing presbyopia are on the horizon, with two approaches currently being studied, according to a speaker here.
“Presbyopia, literally meaning ‘old-eye,’ results in a gradual decrease in lens accommodation, leading to a significant lack of functional near vision. It affects the majority of people over the age of 40, with a target population of 30 to 40 million in the United States, and we have no approved pharmacologic treatment,” Sheri L. Rowen, MD, said at Refractive Subspecialty Day at the American Academy of
Uncategorized